Skip to main content
Figure 3 | The Journal of Headache and Pain

Figure 3

From: Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial

Figure 3

Patient Global Impression of Change (PGIC) results. Evaluation of the PGIC demonstrated that 66.7% of the patients in 25U group reported that their pain symptoms were ‘much improved’ or ‘very much improved’ versus 32.1% of the placebo group (*P < 0.017). In addition, there was a much higher proportion in 75U group (75.9%) compare to the placebo group (*P < 0.017), but there was no significant difference between 25U and 75U groups (P > 0.05).

Back to article page